Taurx

Taurx company information, Employees & Contact Information

Explore related pages

Related company profiles:

TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative brain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders. TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in early trials for participants with mild and moderate Alzheimer's disease. The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial in progress and results recently disclosed. Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care. TauRx Therapeutics Management Ltd is incorporated in Scotland with primary research and operations in Aberdeen.

Company Details

Employees
80
Founded
-
Address
395 King Street, Aberdeen,united Kingdom
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
taurx.com
HQ
Aberdeen
Looking for a particular Taurx employee's phone or email?

Taurx Questions

News

AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator - Clinical Trials Arena

AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator Clinical Trials Arena

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months - Pharmafile

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months Pharmafile

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease - NTB Kommunikasjon

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease NTB Kommunikasjon

Alzheimer’s Disease Next Game Changer: TauRx Pharmaceutical’s Novel Tau Aggregation Inhibitor - Information Technology and Innovation Foundation

Alzheimer’s Disease Next Game Changer: TauRx Pharmaceutical’s Novel Tau Aggregation Inhibitor Information Technology and Innovation Foundation

TauRx seeks UK MHRA approval for Alzheimer’s treatment - Pharmaceutical Technology

TauRx seeks UK MHRA approval for Alzheimer’s treatment Pharmaceutical Technology

Dundee Corporation Completes Sale of 8,000 Shares of TauRx Pharmaceuticals Ltd. for Proceeds of US$1 Million - GlobeNewswire

Dundee Corporation Completes Sale of 8,000 Shares of TauRx Pharmaceuticals Ltd. for Proceeds of US$1 Million GlobeNewswire

TauRx's Alzheimer's trial failed to deliver the pre-specified analyses. It plans to seek approval anyway - Fierce Biotech

TauRx's Alzheimer's trial failed to deliver the pre-specified analyses. It plans to seek approval anyway Fierce Biotech

TauRx Pharmaceuticals | Biotechnology | The Pharmaletter - The Pharma Letter

TauRx Pharmaceuticals | Biotechnology | The Pharmaletter The Pharma Letter

FDA Grants Orphan-drug Designation for TauRx's LMTX in Frontotemporal Dementia - PR Newswire UK

FDA Grants Orphan-drug Designation for TauRx's LMTX in Frontotemporal Dementia PR Newswire UK

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March - Business Wire

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March Business Wire

TauRx sees path to FDA filing for tau-targeting Alzheimer's drug - pharmaphorum

TauRx sees path to FDA filing for tau-targeting Alzheimer's drug pharmaphorum

TauRx shares phase 3 trial data for Alzheimer’s drug - PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug PMLiVE

Second Phase 3 Study Results for LMTX® Published in the Journal of Alzheimer's Disease - PR Newswire

Second Phase 3 Study Results for LMTX® Published in the Journal of Alzheimer's Disease PR Newswire

‘Blue Pee’ Saga Continues: Scientists Still Skeptical About TauRx Alzheimer’s Pill - Being Patient

‘Blue Pee’ Saga Continues: Scientists Still Skeptical About TauRx Alzheimer’s Pill Being Patient

Singapore's TauRx PhIII fails in mild to moderate Alzheimer's trial - Fierce Pharma

Singapore's TauRx PhIII fails in mild to moderate Alzheimer's trial Fierce Pharma

Alzheimer's drug trial supported by Aberdeen research shows 'evidence of sustained improvement' - University of Aberdeen

Alzheimer's drug trial supported by Aberdeen research shows 'evidence of sustained improvement' University of Aberdeen

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data - Pharmaceutical Technology

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data Pharmaceutical Technology

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial - Business Wire

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial Business Wire

TauRx misses primary endpoints in Alzheimer’s combo PhIII trial - Fierce Biotech

TauRx misses primary endpoints in Alzheimer’s combo PhIII trial Fierce Biotech

Singapore's TauRx slated to update on PhIII Alzheimer's trials - Fierce Pharma

Singapore's TauRx slated to update on PhIII Alzheimer's trials Fierce Pharma

Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau - Media OutReach Newswire

Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau Media OutReach Newswire

All Eyes On Genting’s TauRx Alzheimer Phase 3 Trial - BusinessToday Malaysia

All Eyes On Genting’s TauRx Alzheimer Phase 3 Trial BusinessToday Malaysia

Genting hopes 20% associate TauRx’s Alzheimer’s drug gets approval soon - The Edge Malaysia

Genting hopes 20% associate TauRx’s Alzheimer’s drug gets approval soon The Edge Malaysia

Genting to hit jackpot from TauRx? - The Malaysian Reserve

Genting to hit jackpot from TauRx? The Malaysian Reserve

Genting's 20%-owned TauRx says new data on Alzheimer's drug show sustained benefits - The Edge Malaysia

Genting's 20%-owned TauRx says new data on Alzheimer's drug show sustained benefits The Edge Malaysia

Genting’s R&D affiliate TauRx could launch Alzheimer’s drug by 2023 if trials succeed - The Edge Malaysia

Genting’s R&D affiliate TauRx could launch Alzheimer’s drug by 2023 if trials succeed The Edge Malaysia

Genting's 20.7%-owned TauRx to meet EMA and FDA - The Edge Malaysia

Genting's 20.7%-owned TauRx to meet EMA and FDA The Edge Malaysia

Genting and TauRx applying for UK, US regulators' approval for Alzheimer's drug - NST Online

Genting and TauRx applying for UK, US regulators' approval for Alzheimer's drug NST Online

Genting-backed TauRx to seek regulatory approval for Alzheimer's drug - The Edge Malaysia

Genting-backed TauRx to seek regulatory approval for Alzheimer's drug The Edge Malaysia

Genting may get to raise shareholding in TauRx for cheap — Maybank IB Research - The Edge Malaysia

Genting may get to raise shareholding in TauRx for cheap — Maybank IB Research The Edge Malaysia

All eyes on Genting's TauRx wager - The Edge Malaysia

All eyes on Genting's TauRx wager The Edge Malaysia

Genting’s target price may be raised on TauRx bet, says Maybank IB - The Edge Malaysia

Genting’s target price may be raised on TauRx bet, says Maybank IB The Edge Malaysia

Genting betting on TauRX - The Edge Malaysia

Genting betting on TauRX The Edge Malaysia

Top Taurx Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant